Extracellular vesicles derived from EphB2-overexpressing bone marrow mesenchymal stem cells ameliorate DSS-induced colitis by modulating immune balance.

Ting YuSi ChuXingxing LiuJunyi LiQianyun ChenMeng XuHui WuMingyue LiYalan DongFeng ZhuHaifeng ZhouDesheng HuHeng Fan

Published in: Stem cell research & therapy (2021)

Our results suggest that EphB2-EVs have high colonic targeting ability and could mitigate DSS-induced colitis via maintaining colonic immune homeostasis. These findings provide an effective therapeutic strategy for UC treatment in clinic.

Keyphrases

ulcerative colitis
primary care
signaling pathway
cancer therapy
drug delivery
combination therapy